Uninterrupted edoxaban therapy in patients undergoing AF ablation has not been tested.Hohnloser, Stefan H.Camm, JohnCappato, RiccardoDiener, Hans-ChristophHeidbuechels, HeinMonth, LluisMorillo, Carlos A.Abozguia, KhalidGrimaldi, MassimoRauer, HeikoReimitz, Paul-EgbertSmolnik, RuedigerMoenninghoff, ...
Warfarin is widely used, but its dominance is being challenged by novel non-vitamin-K antagonist oral anticoagulants such as dabigatran, rivaroxaban, apixaban, and edoxaban.201 Individual response to warfarin is highly variable and is monitored by INR (see Box 11.1).202 A 10% increase in time ...
A clinical study in which the Xa-targeting DOAC edoxaban was administered to healthy individuals and patients with Child A or B cirrhosis confirmed decreased anticoagulant capacity of this drug in cirrhosis as evidenced by a more modest decrease in ex vivo thrombin generation. Importantly, edoxaban ...
Edoxaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2013;369(22):2093-2104.PubMedGoogle ScholarCrossref 6. National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. Tissue plasminogen activator for acute ischemic stroke. N Engl J Med. ...
Patients were excluded if they were taking any non-VKA anticoagulant or combination of anticoagulants (a direct oral anticoagulant [dabigatran, rivaroxaban, apixaban, or edoxaban], argatroban, desirudin, fondaparinux, low-molecular-weight heparin, lepirudin, unfractionated heparin, or another specified or...
Recent European consensus guide- lines from 2015 recommend oral FXa inhibitors (rivaroxaban, apixaban, or edoxaban) over VKAs in the elderly if CrCl >1 5 ML/min, and in Denmark, we follow the European guidelines, but with the modification that VKA is also recommended if time in ...
Among patients with non-valvular AF, 93,691 used NOAC and 27,496 used warfarin (Fig. 1). The NOAC users were categorized according to medications: dabigatran (n = 11,238; 12.0%), rivaroxaban (n = 28,732; 30.1%), apixaban (n = 20,019; 21.4%), edoxaban (n = ...
Background and purpose: Venous thromboembolism (VTE), comprising deep-vein thrombosis and pulmonary embolism, is associated with significant morbidity and mortality. Non-vitamin K oral anticoagulants (NOACs), including apixaban, betrixaban, dabigatran, edoxaban, and rivaroxaban, are as effective and safe...
31 However, the question whether low-dose treatment with the Factor Xa inhibitor edoxaban as compared to patients without OAC would impact on kidney outcomes was not addressed in this study.31 Annual mortality was high in the XARENO study population which is in agreement with the mean age of ...
NOACs were defined as the preceding use of dabigatran, rivaroxaban, apixaban, or edoxaban. Patients were excluded from the analysis if they were taking 2 or more anticoagulant agents (both NOACs and warfarin, or NOAC or warfarin with other anticoagulants such as heparin and low-molecular-weight...